Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 2/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.44 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.42 |
| ▸ | MTNR1A | P48039 | 2/20 | 0.41 |
| ▸ | NQO2 | P16083 | 1/20 | 0.41 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | CDYL | Q9Y232 | 1/20 | 0.40 |
| ▸ | ACP3 | P15309 | 1/20 | 0.40 |
| ▸ | KCNA5 | P22460 | 1/20 | 0.39 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL586305 | 0.91 | CYP1A2 (0.52) | CYP1A2CYP2C19CYP2C9CYP2D6MTNR1A | |
| SCHEMBL5015032 | 0.90 | GPR84 (0.42) | CYP1A2CYP2C19CYP2C9CYP2D6MTNR1A | |
| SCHEMBL6420346 | 0.84 | CYP1A2 (0.46) | CYP1A2CYP2C19CYP2C9CYP2D6TDP1 | |
| SCHEMBL11052717 | 0.82 | CYP1A2 (0.46) | CYP1A2CYP2C19CYP2C9CYP2D6MTNR1A | |
| SCHEMBL4521520 | 0.82 | MTNR1A (0.45) | CYP1A2CYP2C19CYP2C9CYP2D6MTNR1A | |
| SCHEMBL2092694 | 0.81 | SIGMAR1 (0.42) | CYP1A2CYP2C19CYP2C9CYP2D6MTNR1A | |
| SCHEMBL129188 | 0.81 | CYP1A2 (0.54) | CYP1A2CYP2C19CYP2C9CYP2D6MTNR1A | |
| SCHEMBL11051055 | 0.80 | CYP1A2 (0.47) | CYP1A2CYP2C19CYP2C9CYP2D6MTNR1A | |
| SCHEMBL3779748 | 0.79 | CYP1A2 (0.48) | CYP1A2CYP2C19CYP2C9CYP2D6MTNR1A | |
| SCHEMBL14814398 | 0.79 | CNR1 (0.43) | CYP1A2CYP2C19CYP2C9MTNR1ATDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100179218-A1 | OCULOSELECTIVE DRUGS AND PRODRUGS | QLT INC. (CA) | 2010-07-15 | — | — | US | disclosed |
| US-7678829-B2 | Oculoselective drugs and prodrugs | QLT INC. (CA) | 2010-03-16 | — | — | US | disclosed |
| US-20070254950-A1 | Oculoselective Drugs and Prodrugs | OTHERA PHARMACEUTICALS, INC. (US) | 2007-11-01 | — | — | US | disclosed |
| EP-1750693-A1 | OCULOSELECTIVE DRUGS AND PRODRUGS | Othera Pharmaceuticals, Inc. (US) | 2007-02-14 | — | — | EP | disclosed |
| US-20060019955-A1 | Oculoselective drugs and prodrugs | OTHERA PHARMACEUTICALS, INC. (US) | 2006-01-26 | — | — | US | disclosed |
| WO-2005115375-A1 | OCULOSELECTIVE DRUGS AND PRODRUGS | OTHERA PHARMACEUTICALS, INC. (US) | 2005-12-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060019955-A1 | Oculoselective drugs and prodrugs | HCAR3, CNKSR1, HCRTR1 | CYP1A2 272/4885CYP2C19 447/4885CYP2C9 169/4885 |
| US-20100179218-A1 | OCULOSELECTIVE DRUGS AND PRODRUGS | ALDH1A2, CYP2D6, PDE6C | CYP1A2 31/4885CYP2C19 5/4885CYP2C9 12/4885 |
| US-20070254950-A1 | Oculoselective Drugs and Prodrugs | CNKSR1, HCAR3, HCRTR1 | CYP1A2 213/4885CYP2C19 285/4885CYP2C9 87/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.